Accelerate Diagnostics, Inc.

Equities

AXDX

US00430H2013

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:00:00 2024-04-19 pm EDT 5-day change 1st Jan Change
0.859 USD +11.56% Intraday chart for Accelerate Diagnostics, Inc. -3.27% -78.09%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Accelerate Diagnostics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Accelerate Diagnostics, Inc., Q4 2023 Earnings Call, Mar 28, 2024
Accelerate Diagnostics, Inc. announced that it expects to receive $4.749996 million in funding from Jack W. Schuler Living Trust CI
Top Midday Decliners MT
Sector Update: Health Care Stocks Weaker Late Afternoon MT
Sector Update: Health Care MT
Top Midday Decliners MT
Accelerate Diagnostics, Inc. Announces Preliminary Unaudited Revenue Results for the Year Ended December 31, 2023 CI
Accelerate Diagnostics Announces Collaboration for the Use of the Arc System in Combination With Bruker´s MALDI Biotyper CI
Accelerate Diagnostics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Accelerate Diagnostics, Inc., Q3 2023 Earnings Call, Nov 09, 2023
Earnings Flash (AXDX) ACCELERATE DIAGNOSTICS Posts Q3 Revenue $3.3M MT
Transcript : Accelerate Diagnostics, Inc., Q2 2023 Earnings Call, Aug 10, 2023
Earnings Flash (AXDX) ACCELERATE DIAGNOSTICS Reports Q2 Revenue $2.9M MT
Accelerate Diagnostics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Accelerate Diagnostics to Conduct 1-for-10 Reverse Stock Split; Shares Fall MT
Accelerate Diagnostics, Inc.(NasdaqCM:AXDX) dropped from Russell Microcap Growth Index CI
Accelerate Diagnostics, Inc.(NasdaqCM:AXDX) dropped from Russell Microcap Index CI
Accelerate Diagnostics, Inc.(NasdaqCM:AXDX) dropped from Russell 3000E Index CI
Accelerate Diagnostics, Inc.(NasdaqCM:AXDX) dropped from Russell 3000E Growth Index CI
Accelerate Diagnostics, Inc. announced that it expects to receive $10 million in funding from Chicago Venture Partners, L.P., PenderFund Capital Management Ltd., Wolverine Asset Management, LLC, RBC CMA LLC and other investor CI
Accelerate Diagnostics, Inc. is Heading Towards Bankruptcy CI
Transcript : Accelerate Diagnostics, Inc., Q1 2023 Earnings Call, May 11, 2023
Earnings Flash (AXDX) ACCELERATE DIAGNOSTICS Posts Q1 Revenue $2.8M MT
Accelerate Diagnostics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Chart Accelerate Diagnostics, Inc.
More charts
Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions for the global challenges of antibiotic resistance and sepsis. Its Accelerate Pheno system and Accelerate PhenoTest BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the optimal antibiotic therapy for deadly infections. The United States Food and Drug Administration (FDA) cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately seven hours direct from positive blood cultures. The Accelerate PhenoTest BC Kit, which is the first test kit for the system, is indicated as an aid, in conjunction with other clinical and laboratory findings, in the diagnosis of bacteremia and fungemia, both life-threatening conditions with high morbidity and mortality risk. Its other products include Accelerate Arc system and BC Kit (Accelerate Arc Products) and Accelerate Wave system.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.77
Average target price
-
Consensus